BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol 2015;17:996-1004. [PMID: 26691658 DOI: 10.1007/s12094-015-1456-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 De Mello RA. Gastric Cancer in Southern Europe: High-Risk Disease. Am Soc Clin Oncol Educ Book 2017;37:261-6. [PMID: 28561674 DOI: 10.1200/EDBK_175227] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Yang L, Xu JF, Kang Q, Li AQ, Jin P, Wang X, He YQ, Li N, Cheng T, Sheng JQ. Predictive Value of Stemness Factor Sox2 in Gastric Cancer Is Associated with Tumor Location and Stage. PLoS One 2017;12:e0169124. [PMID: 28046028 DOI: 10.1371/journal.pone.0169124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
3 Bruna Esteban M, Ortíz Escandell MÁ, Parilla Paricio P. Cancer of the esophagogastric junction: A border in continuous movement. Cir Esp (Engl Ed) 2019;97:425-6. [PMID: 31164216 DOI: 10.1016/j.ciresp.2019.03.003] [Reference Citation Analysis]
4 Casamayor M, Morlock R, Maeda H, Ajani J. Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience. 2018;12:883. [PMID: 30679950 DOI: 10.3332/ecancer.2018.883] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
5 Li N, Wu L, Zuo X, Luo H, Sheng Y, Yan J. USP1 Promotes GC Metastasis via Stabilizing ID2. Dis Markers 2021;2021:3771990. [PMID: 34873426 DOI: 10.1155/2021/3771990] [Reference Citation Analysis]
6 Pericay C, Macías-Declara I, Arrazubi V, Vilà L, Marín M. Treatment in esophagogastric junction cancer: Past, present and future. Cir Esp (Engl Ed) 2019;97:459-64. [PMID: 31155142 DOI: 10.1016/j.ciresp.2019.03.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Bencivenga M, Torroni L, Verlato G, Mengardo V, Sacco M, Allum WH, de Manzoni G. Lymphadenectomy for gastric cancer at European specialist centres. Eur J Surg Oncol 2021;47:1048-54. [PMID: 33092970 DOI: 10.1016/j.ejso.2020.10.013] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Alhusaini A, Cannon A, Maher SG, Reynolds JV, Lynam-Lennon N. Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers. Biomedicines 2021;9:1024. [PMID: 34440228 DOI: 10.3390/biomedicines9081024] [Reference Citation Analysis]
9 Li HZ, Chen JX, Zheng Y, Zhu XN. Laparoscopic-assisted versus open radical gastrectomy for resectable gastric cancer: Systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials. J Surg Oncol 2016;113:756-67. [PMID: 27076039 DOI: 10.1002/jso.24243] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
10 Orman S, Cayci HM. Gastric cancer: factors affecting survival. Acta Chir Belg 2019;119:24-30. [PMID: 29560799 DOI: 10.1080/00015458.2018.1453437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
11 Huang L, Zhang X, Wei Z, Xu A. Importance of Examined Lymph Node Number in Accurate Staging and Enhanced Survival in Resected Gastric Adenocarcinoma-The More, the Better? A Cohort Study of 8,696 Cases From the US and China, 2010-2016. Front Oncol 2020;10:539030. [PMID: 33585181 DOI: 10.3389/fonc.2020.539030] [Reference Citation Analysis]
12 Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol 2019;83:1175-81. [PMID: 30927036 DOI: 10.1007/s00280-019-03820-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
13 Rodriguez CA, Martín M. SEOM Guidelines 2015: a new era in the collaboration with the Spanish Cancer Research Cooperative Groups. Clin Transl Oncol 2015;17:937-8. [PMID: 26680634 DOI: 10.1007/s12094-015-1478-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Aytaç E, Aslan F, Çicek B, Erdamar S, Gürses B, Güven K, Falay O, Karahasanoğlu T, Selçukbiricik F, Selek U, Atalar B, Balık E, Tözün N, Rozanes İ, Arıcan A, Hamzaoğlu İ, Baca B, Molinas Mandel N, Saruç M, Göksel S, Demir G, Ağaoğlu F, Yakıcıer C, Özbek U, Özben V, Özyar E, Güner AL, Er Ö, Kaban K, Bölükbaşı Y, Buğra D, Group Tİ. Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group. Turk J Gastroenterol 2019;30:584-98. [PMID: 30541724 DOI: 10.5152/tjg.2018.18737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Karavokyros I, Michalinos A. Favoring D2-Lymphadenectomy in Gastric Cancer. Front Surg 2018;5:42. [PMID: 29930941 DOI: 10.3389/fsurg.2018.00042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 Marrelli D, De Franco L, Iudici L, Polom K, Roviello F. Lymphadenectomy: state of the art. Transl Gastroenterol Hepatol 2017;2:3. [PMID: 28217753 DOI: 10.21037/tgh.2017.01.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]